Recruiting

NCT Number: NCT07140757

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Low Risk Adenocarcinoma Adenocarcinoma, Papillary Carcinoma Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Papillary Thyroid Cancer Radiofrequency Ablation Thyroid Cancer, Papillary Thyroid Diseases Thyroid Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Victoria E Banuchi, MD

CONTACT

[email protected]

346-217-8668

Victoria E Banuchi, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objectives

To evaluate thyroid nodule volume changes over time in participants undergoing RFA as part of clinical care

Secondary Objectives

To establish the health-related quality of life among participants undergoing with ultrasound guided RFA.
To evaluate the sonographic features of thyroid nodules over time following ultrasound guided RFA.
To assess adverse events rates following ultrasound guided RFA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Eligibility Criteria

Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC
Participant is over 18 years and is either not a surgical candidate or has declined surgery.
Capable and willing to provide written informed consent
Participant has one of the following diagnoses:

Biopsy-proven benign thyroid nodules causing compressive and/or cosmetic symptoms who are requesting treatment,
Biopsy-proven indeterminate nodules (AUS or follicular neoplasm)
Papillary thyroid carcinoma (PTC) without metastasis
Locally recurrent thyroid cancer (< 2 cm).

Exclusion criteria

Participants meeting any of the following criteria will be excluded:
Participants considered unsuitable for RFA by the treating physician

Treatment and study plan

Questionnaire

Other

This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.

Primary outcomes

Health- related Quality of Life Questionnaires

Time frame: Through study completion; an average of 1 year

This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.

Study contacts

Contact information is provided by the study sponsor or research team.

Victoria E Banuchi, MD

CONTACT

[email protected]

346-217-8668

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2028
Study completion: 2030
First posted: Aug 26, 2025
Registry last updated: Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting